[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Coronavirus, Global weekend update", "description": "Global\n\nCases, 24, 770, 101\n\nDeaths, 837,853\n\nMore than twice as many new cases in past 28 days\n\nhttps://www.dw.com/en/coronavirus-global-pandemic-trend/a-53954594\n\nAsia\nJordan, Lebanon, Myanmar, South Korea\n\nAfrica\nChad, Eritrea, Ethiopia, Namibia, Rwanda, Somalia, Tunisia, Uganda\n\nAmericas\nBermuda, British Virgin Islands, Curacao, Guyana, Jamaica, Paraguay, Trinidad and Tobago\n\nEurope\nAustria, Croatia, France, Gibraltar, Italy, Liechtenstein, Slovenia\n\nOceania\nFrench Polynesia, Guam, New Zealand\n\nGermany\n\nCases, + 1,571 = 239, 507\n\nhttps://www.dw.com/en/coronavirus-germanys-angela-merkel-warns-of-hard-months-to-come/a-54727205\n\nLife cannot get back to normal until a vaccine is found\n\nhttps://www.dw.com/en/germany-coronavirus-measures-masks/a-54714744\n\nExtend ban on major public events to next year (all 16 regions)\n\nFine of \u20ac50 ($60), not wearing a mask in shops and on public transport\n\nDrivers of infection\n\nLocal celebrations\n\nReturning holidaymakers\n\nNegligence, hygienic, social distancing measures \n\nNo decision on Christmas markets, Carnival\n\nUK, ONS, week ending 14 August 2020 (Week 33)\n\nCases, 333, 806\n\nDeaths, 41, 573\n\nDeaths, 52,091 (England and Wales, weeks 1 - 33)\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19roundup/2020-03-26\n\nhttps://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsregisteredweeklyinenglandandwalesprovisional/latest\n\nWeek ending 14 August (Week 33)\n\n28,200 community, England (0.05% of the community population)\n\nDeaths involving COVID-19 (England and Wales), 139 (1.5% of all deaths in that week)\n\nThe number of deaths involving COVID-19 decreased or remained the same across the majority of the English regions\n\nDeaths increased in London\n\nTracker app\n\nNew daily cases, 1, 292\n\nActive cases, 19, 381\n\nGreater Manchester, Lancashire, West Yorkshire\n\nJuly, 30th, four million people ordered not to household mix\n\nLifting Sept. 2\n\nSpain\n\nCases, 439, 286\n\nDeaths, 29, 011\n\nSchoolchildren aged six and over must wear masks to class\n\nUS\n\nCases, 5, 918, 381\n\nDeaths, 181, 779\n\nhttps://www.telegraph.co.uk/global-health/science-and-disease/uk-coronavirus-news-covid-deaths-second-wave-face-masks/\n\nPresident\n\n150 million rapid Covid-19 tests\n\nAbbott Laboratories, $750 million\n\n$5 \n\nSafe and effective vaccine this year\n\nSeven US states\n\nDisregard reduced testing on those exposed and asymptomatic\n\nCalifornia, Connecticut, Florida, Illinois, Texas, New Jersey and New York \n\nPlan to continue to test asymptomatic people who have been exposed\n\nRisk of early testing negative\n\nMass gatherings in Washington\n\n\nNevada\n\nhttps://www.youtube.com/watch?v=YUutJPtT8QA\n\nOne case of reinfection\n\nCanada\n\nPopulation, 38m \n\nCases, 129, 342\n\nDeaths, 9,155\n\nhttps://www.theguardian.com/world/live/2020/aug/28/coronavirus-live-news-tour-de-france-in-doubt-who-to-review-emergency-alert-rules?page=with:block-5f495f798f08ac62b0fb1ce0#liveblog-navigation\n\nExtended, barring most foreign travellers to 30 September\n\nSeparate agreement with the United States, until 21 September.\n\n\nAustralia\n\nhttps://www.dhhs.vic.gov.au/victorias-restriction-levels-covid-19\n\nVictoria\n\nCases, + 94\n\nNew cases, below 100\n\nFirst time since 5 July\n\n4,223 cases of unknown origin\n\nDeaths, + 18 deaths, (16 aged care)\n\nMelbourne, another fortnight of strict stage-four restrictions\n\nPolice spot checks, fines and arrests\n\nMetropolitan Melbourne, Stage 4 restrictions apply\n\nCurfew, 8pm until 5am, work, medical care and caregiving\n\nLeaving home, shopping for food, exercise with one other person, permitted work\n\nCaregiving, medical treatment\n\nAs much as you can, you must stay at home\n\nFace covering\nNZ\n\nhttps://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-situation/covid-19-current-cases\n\nhttps://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus\n\nCases, + 13\n\n137 active cases\n\ntracing and testing all close contacts of these cases\n\nAll close contacts will remain in self-isolation for 14 days\n\nIndia \n\nCases, + 62, 539 = 3, 463, 972\n\nHighest one day rise\n\nDeaths, 62, 550\n\nWHO trip to China\n\nhttps://www.telegraph.co.uk/news/2020/08/27/covid-19-team-three-week-mission-china-does-not-visit-wuhan/\n\nOrigins of coronavirus\n\nDid not visit Wuhan\n\nVideo meetings from quarantine\n\nInternational investigation into the origins of Sars-Cov-2\n\nDave Sharma, Australian MP\n\nIt is another disturbing incident of the WHO - which is charged with safeguarding global public health - putting the political sensitivities of a member state above the public health interests of the world\n\nLarger team later this year\nChinese scientists, currently at work", "link": "https://www.youtube.com/watch?v=L0ygkjSKNXI", "date_published": "2020-08-29 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic Science, Reinfections and hydroxychloroquine", "description": "2 European reinfections\n\nhttps://www.independent.co.uk/news/health/coronavirus-reinfection-netherlands-belgium-hong-kong-covid-19-update-a9687301.html\n\nNetherlands \n\nMarion Koopmans (virologist)\n\nViral genomes were different\n\nOlder person with a weakened immune system\n\nReinfections had been expected.\n\nWe have to see whether it happens often\n\nBelgium\n\nWoman, first time in March, second time in June\n\nMarc Van Ranst (virologist)\n\nWoman\u2019s symptoms relatively mild\n\nMay not have created enough antibodies to prevent a reinfection\n\nThey might have helped limit the sickness\n\nI think that in the coming days that we will see other similar stories\n\nIt\u2019s not good news\n\nHow common\n\nHigh levels of surveillance\n\nUse of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study (European Journal of Internal Medicine,\n\nImmunomodulatory\n\nAnti-inflammatory\n\nAnti-thrombotic\n\nDirectly inhibits viral entry and spread in several in vitro and in vivo models \n\nMight inhibit ACE 2, reduced internalization of the virus \n\nhttps://www.ejinme.com/article/S0953-6205(20)30335-6/fulltext \n\nhttps://www.ejinme.com/action/showPdf?pii=S0953-6205%2820%2930335-6\n\nMulticenter Italian collaboration, relationship between HCQ therapy and COVID-19 in-hospital mortality\n\nMethods\n\nRetrospective observational study\n\nN = 3,451\n\n33 clinical centers in Italy\n\nFebruary 19th to May 23rd \n\nLaboratory-confirmed SARS-CoV-2 infection\n\nComparing patients who received HCQ with patients who did not\n\nDose\n\nHCQ, all centres, 400 mg/day \n\nOne centre, 600 mg/day\n\n5 to 15 days\n\nDose, BNF link\n\nhttps://bnf.nice.org.uk/drug/hydroxychloroquine-sulfate.html\n\nResults\n\nOut of 3,451\n\n76.3% received HCQ\n\nHCQ group\n\nN  = 2633\n\nDeath rate 8.9\n\nPer, 1,000 person days\n\nNon HCQ group\n\nN = 817\n\nDeath rate 15.7\n\nAfter adjustment for propensity scores\n\n30% lower risk of death in patients receiving HCQ\n\nHR=0.70;\n\n95%CI: 0.59 to 0.84;\n\nHCQ use was associated with a 30% reduced death rate\n\n95%CI: 16% to 41%\n\nThese data do not discourage the use of HCQ in inpatients with COVID-19\n\nEffect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis (26 August, Clinical Microbiology and Infection, France)\n\nhttps://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30505-X/fulltext\n\nhttps://www.clinicalmicrobiologyandinfection.com/action/showPdf?pii=S1198-743X%2820%2930505-X\n\n839 articles\n\n29 articles met our inclusion criteria\n\nIncluding 3 RCTs\n\nEvaluated the effects of hydroxychloroquine with or without azithromycin (except one)\n\nMeta-analysis \n\nHydroxychloroquine group\n\nn = 11,932 participants for the,\n\nAssociation with mortality\n\nRR = 0.83 (not significant)\n\nHydroxychloroquine with azithromycin group\n\nN = 8081\n\nRR = 1.27\n\nIncreased risk or mortality\n\nWe identified a significant absolute risk difference of +7%\n\nControl group\n\nN = 12,930\n\nConclusion\n\nHydroxychloroquine alone was not associated with reduced mortality in hospitalized COVID-19 patients\n\nthe combination of hydroxychloroquine and azithromycin significantly increased mortality\n\n\nWHO, Solidarity clinical trial for COVID-19 treatments\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments\n\nOn 4 July 2020, WHO accepted the recommendation from the Solidarity Trial\u2019s International Steering Committee to discontinue the trial\u2019s hydroxychloroquine and lopinavir/ritonavir arms.\n\nWHO dose in Solidarity trial\n\nhttps://www.palmerfoundation.com.au/who-solidarity-and-uk-recovery-clinical-trials-of-hydroxychloroquine-using-potentially-fatal-doses/\n\nCanadian arm\n\nhttps://clinicaltrials.gov/ct2/show/NCT04330690\n\nTreatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)\n\nHydroxychloroquine 800mg BID for 1 day\n\nthen 400mg BID for 10 days plus optimized supportive care,\n\nLancet, retracted paper\n\nhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext#%20\n\nWe were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide\n\n\nRisk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study (lancet 21st august\n\nhttps://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30276-9/fulltext\n\nRetrospective, multinational, cohort\n\nN = 956 374 \n\nHydroxychloroquine treatment appears to have no increased risk in the short term among patients with rheumatoid arthritis\n\nLong term it appears to be associated with excess cardiovascular mortality\n\nThe addition of azithromycin increases the risk of heart failure and cardiovascular mortality \neven in the short term. \n\nWe call for careful consideration of the benefit\u2013risk trade-off when counselling those on hydroxychloroquine treatment.", "link": "https://www.youtube.com/watch?v=SBn4e69tGlg", "date_published": "2020-08-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pandemic update from Iraq", "description": "Professor Raghad Alsuhail from Iraq bring us up to date with developments in her country. Raghad is Professor of virology and immunology at the University of Baghdad.", "link": "https://www.youtube.com/watch?v=J2pt7owNsBU", "date_published": "2020-08-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]